10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
Michael Lübbert(University of Freiburg), Mario Luppi(University of Modena and Reggio Emilia), Robin Foà(Sapienza University of Rome), Walter J. F. M. van der Velden(Radboud University Nijmegen), Frédéric Baron(University of Liège), Heiko Becker(University of Freiburg), Joop H. Jansen(Radboud University Nijmegen), Eduardus F. M. Posthuma(Leiden University Medical Center), Sylvain Chantepie(Centre Hospitalier Universitaire de Caen Normandie), Fabio Efficace(Fondazione Gimema Onlus), Mels Hoogendoorn(Medisch Centrum Leeuwarden), Michal Kiciński(European Organisation for Research and Treatment of Cancer), Gerwin Huls(University Medical Center Groningen), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Stephan Fuhrmann(Helios Hospital Berlin-Buch), Andreas Neubauer(RWTH Aachen University), Stefan Suciu(European Organisation for Research and Treatment of Cancer), Aniek O. de Graaf(Radboud University Nijmegen), Radovan Vrḫovac(University Hospital Centre Zagreb), Daniëlle van Lammeren‐Venema(Haga Hospital), Emanuele Ammatuna(University Medical Center Groningen), Laimonas Griškevičius(Vilnius University), Nicole M. A. Blijlevens(Radboud University Nijmegen), Marian Stevens‐Kroef(Radboud University Nijmegen), Sergio Amadori(Polyclinic Medical Center), Richard Noppeney(Essen University Hospital), Ulrich Dührsen(Essen University Hospital), Ralph Wäsch(University of Freiburg), Martina Crysandt(RWTH Aachen University), Ernesta Audisio(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Jean‐Pierre Vilque(Centre Hospitalier Universitaire de Caen Normandie), Pierre W. Wijermans(Radboud University Nijmegen), Olivier Legrand(Inserm), Anna Candoni(University of Udine), Adriano Venditti(University of Rome Tor Vergata)
Cited by 39
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k